MONT-SAINT-GUIBERT, Belgium, October 23, 2013 /PRNewswire/ --
• CHART-1 trial represents the world's first Phase III trial in regenerative medicine for a pre-programmed cellular therapy targeting heart failure
• To date, seven countries have granted authorization for Cardio3 BioSciences' Phase III (CHART-1)
• Six leading clinical centers will participate in CHART-1 in Italy
The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces it has received authorization from the Italian Medicines Agency (AIFA) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure® in Italy.
After the recent authorization in Spain, and earlier in United Kingdom, Belgium, Israel, Serbia and Hungary, Italy is the seventh country to have authorized this unique study. There will be six leading clinical centers participating to the trial in Italy.
The CHART-1 trial represents the world's first Phase III trial for a pre-programmed cellular therapy targeting heart failure.
Professor Marco Metra, the Principal Investigator in Italy commented: "We are proud to participate in this Phase III trial evaluating the benefit of C-Cure® cardiopoietic cells for the treatment of severe heart failure.We believe that theCHART-1 studyis oneof the most importantcurrent studieson improving thetreatment of chronicheart failure.We hopethat this innovativetreatment willimprovethe qualityof life of patientssuffering from thisprogressiveanddebilitating disease, one of the most importantunmetmedical needs today. E' tempo d'iniziare! Anche nel nostro paese! "
Dr Christian Homsy, CEO of Cardio3 BioSciences, said: "We are verypleased with the progressof ourPhaseIII clinical study. Adding another bigEuropeancountry likeItaly, which will open six sites,will enable usto pursue the studyaccording toour development plan."
The Phase III trial is a prospective, multi-centre, randomized, sham-controlled, patient-and evaluator-blinded study comparing treatment with C-Cure® to a sham treatment. The trial will recruit a minimum of 240 patients with chronic advanced symptomatic heart failure. The primary endpoint of the trial is a composite endpoint including mortality, morbidity, quality of life, Six Minute Walk Test and left ventricular structure and function at 9 months post-procedure.
If you want to subscribe to the company newsletter, please fill in the subscription form on the website href="http://www.c3bs.com" rel="nofollow">http://www.c3bs.com
Upcoming financial events
12 November 2013 : Business Update Q3 2013
22-23 November 2013 : Actionaria -Listed companies & financial products Fair - Palais des Congrès Paris
About Cardio3 BioSciences
Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.
The Company's lead product candidate C-Cure® is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure® consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle cells that behave identically to those lost to heart disease. This process is known as Cardiopoiesis.
Cardio3 BioSciences has also developed C-Cath®ez, the most technologically injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.
Cardio3 BioSciences' shares are listed on NYSE Euronext Brussels and NYSE Euronext Paris under the ticker symbol CARD.
Help employers find you! Check out all the jobs and post your resume.